Paysign, Inc. (NASDAQ: PAYS) reported Q4 EPS of $0.02, in-line with the analyst estimate of $0.02. Revenue for the quarter came in at $15.61 million versus the consensus estimate of $15.45 million.

2025 Outlook

“We delivered on another year of solid operating results with our patient affordability business becoming a meaningful contributor to the growth in our revenue and business diversification strategy that we began focusing on six years ago. In 2024 our patient affordability business represented 21.7% of our revenue, a significant increase from the 8.5% of revenue it contributed in 2023. In 2025 we expect that percentage to significantly increase again to at least 37.0% of our revenue. As we have started to experience a near-term slowdown in our plasma business due to an industry-wide oversupply of plasma, we will continue to utilize the cash flow from this business to invest in our patient affordability business and engage in impactful acquisitions like the one we announced this morning,” said Jeff Baker, Paysign CFO.

For earnings history and earnings-related data on Paysign, Inc. (PAYS) click here.